Logotype for Valmet

Valmet (VALMT) CMD 2025 summary

Event summary combining transcript, slides, and related documents.

Logotype for Valmet

CMD 2025 summary

17 Sep, 2026

Strategic direction and transformation

  • Launched the 'Lead the Way' strategy to transform industries toward a regenerative future, emphasizing lifecycle commitment, customer-centric operations, and digitalization.

  • Introduced a new operating model, effective July 1, 2025, to simplify structure, empower employees, and drive faster execution.

  • Shifted from continuous improvement to bold, multi-year ambitions, targeting fewer, high-impact strategic initiatives and fostering a high-performance, accountable culture.

  • Strategy anchored on customer success, lifecycle commitment, global competitiveness, and accountability.

  • Emphasizes seamless lifecycle services, cost competitiveness, and continuous innovation to advance circularity and resource efficiency.

Financial targets and performance

  • Set 2030 financial targets: 5% organic net sales CAGR, 15% comparable EBITA/EBITDA margin, 20% ROCE, and gearing below 50%.

  • Biomaterial Solutions and Services targets 8% organic service growth and 14% EBITA margin by 2030; Process Performance Solutions targets 20% EBITA margin and organic growth over double the market rate.

  • EUR 100 million in cost savings targeted by 2030 through global supply consolidation and procurement optimization.

  • Operating model changes expected to deliver EUR 80 million in annual savings starting next year.

  • Dividend payout policy set at a minimum of 50% of profit, with additional share buybacks based on capital needs.

Business segment developments

  • Biomaterial Solutions and Services reorganized into three business areas with full lifecycle accountability, focusing on pulp, energy, packaging, and tissue.

  • Service share in biomaterials segment at 50%, with plans to grow market share from 21% to 25% organically by 2030.

  • Process Performance Solutions aims to accelerate growth in diversified industries, leveraging digitalization, mission-critical solutions, and recent technology releases and acquisitions.

  • Unique competitive advantage in full tissue lifecycle delivery, enhanced by recent acquisitions such as Körber, FactoryPal, and gas chromatography.

  • R&D focus shifting to customer co-creation, longer-term investments, and targeted innovation in resource efficiency.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more